Our Core Research Partners

HerpeZ

Diagnostics Research & Training in Zambia

EMPIRICAL - Empirical treatment against cytomegalovirus and tuberculosis in severe pneumonia in HIV-infected infants: a randomized controlled clinical trial

Pneumonia is the main cause of death in HIV-infected children. A significant number of undiagnosed or poorly treated HIV-infected children present to health services with severe pneumonia. WHO guidelines to treat severe pneumonia in HIV-infected infants include empirical treatment against common bacteria plus Pneumocystis jirovecii. Although this approach has contributed to reduce overall case fatality rates, mortality in this particularly vulnerable group remains unacceptably high. Autopsy studies in Africa have shown that cytomegalovirus infection and tuberculosis are important under-diagnosed and under-treated causes of death, each accounting for up to 20% of mortalities in HIV-infected infants. Un-controlled studies from South Africa have shown that ganciclovir can successfully treat cytomegalovirus pneumonia, but there have been no clinical trials demonstrating efficacy in HIV-infected African children to date. The prevalence of unrecognised tuberculosis in HIV-infected infants with severe pneumonia has been estimated to be around 18%. However, this is likely an underestimate, as >50% of children who die of tuberculosis had not been diagnosed ante-mortem. Despite the high mortality associated with tuberculosis and cytomegalovirus, in many resource-limited settings there is no diagnosis in place and available diagnostic tools perform poorly.  Our objective is to evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia. A randomised factorial clinical trial will be conducted in six sub-Saharan African countries to evaluate the safety and efficacy of empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants aged 1 month-12 months admitted to hospital with severe pneumonia. Study end-points include 15-day and 12-month survival. HIV-infected infants will receive standard of care (SoC) pneumonia treatment including antibiotics, cotrimoxazole and prednisolone. Infants with presumptive tuberculosis will receive tuberculosis treatment and will be randomised to receive either SoC plus valganciclovir or SoC. Patients with a diagnosis of non-presumptive tuberculosis will be randomised to receive SoC plus valganciclovir and tuberculosis treatment in a 2x2 factorial randomisation. Causes of death among study participants will be studied using verbal autopsies and minimally invasive autopsies. A drug-to-drug interaction sub-study of antiretrovirals/rifampicin will be assessed in a sub-sample of participants.  We propose an innovative empirical management approach that could result in a decrease of mortality in this highly vulnerable population group.

African Partners

Programme PAC-CI (PAC-CI) (Cote d’Ivoire)

Malawi Liverpool Welcome Trust (MLW) (Malawi)

Centro de Investigação em Saúde da Manhiça (CISM) (Mozambique)

Hospital Central de Maputo (HCM) (Mozambique)

Mulago Hospital-Makerere University (MU) (Uganda)

HerpeZ (Zambia)

University of Zimbabwe (UZ-CRC) (Zimbabwe)

European Partners

Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre (Spain)

Fundación Privada Instituto de Salud Global Barcelona (ISGLobal) (Spain)

School of Life Sciences, University of Lincoln (United Kingdom)

l'Institut national de la santé et de la recherche médicale (INSERM) (France)
Université de Bordeaux (UBx) (France)
Penta Foundation (Italy)
Stichting Katholieke Universiteit- Radboudumc (RUMC) (Netherlands)

Kick-Off Meeting! 

Radisson Blu Lusaka, 19-20th Feb 2019

HerpeZ is delighted to welcome all EMPIRICAL partners to Lusaka on the 19th & 20th Feb 2019, to launch this exciting clinical trial. We hope by now all delegates have their travel plans in order. Please direct any last minute queries to: Dr John Tembo:

e-mail: john.tembo@gmail.com

Phone: +260963942556